These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 30365561)

  • 1. Vaccination by microneedle patch with inactivated respiratory syncytial virus and monophosphoryl lipid A enhances the protective efficacy and diminishes inflammatory disease after challenge.
    Park S; Lee Y; Kwon YM; Lee YT; Kim KH; Ko EJ; Jung JH; Song M; Graham B; Prausnitz MR; Kang SM
    PLoS One; 2018; 13(10):e0205071. PubMed ID: 30365561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants.
    Lee Y; Ko EJ; Kim KH; Lee YT; Hwang HS; Jung YJ; Jeeva S; Kwon YM; Seong BL; Kang SM
    Antiviral Res; 2019 Aug; 168():100-108. PubMed ID: 31150678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus.
    Lee Y; Ko EJ; Kim KH; Lee YT; Hwang HS; Kwon YM; Graham BS; Kang SM
    Virology; 2019 Aug; 534():1-13. PubMed ID: 31163351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
    Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
    Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats.
    Kamphuis T; Stegmann T; Meijerhof T; Wilschut J; de Haan A
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1227-36. PubMed ID: 23575113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
    J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice.
    Kamphuis T; Meijerhof T; Stegmann T; Lederhofer J; Wilschut J; de Haan A
    PLoS One; 2012; 7(5):e36812. PubMed ID: 22590614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG in Combination with an Inhibitor of Notch Signaling Suppresses Formalin-Inactivated Respiratory Syncytial Virus-Enhanced Airway Hyperresponsiveness and Inflammation by Inhibiting Th17 Memory Responses and Promoting Tissue-Resident Memory Cells in Lungs.
    Zhang L; Li H; Hai Y; Yin W; Li W; Zheng B; Du X; Li N; Zhang Z; Deng Y; Zeng R; Wei L
    J Virol; 2017 May; 91(10):. PubMed ID: 28275186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipopolysaccharide Inhibits FI-RSV Vaccine-enhanced Inflammation Through Regulating Th Responses.
    Yin W; Li HY; Zheng BY; Deng YQ; Li WJ; Liu Y; Zeng RH
    Curr Med Sci; 2019 Jun; 39(3):363-370. PubMed ID: 31209804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alum Adjuvant Enhances Protection against Respiratory Syncytial Virus but Exacerbates Pulmonary Inflammation by Modulating Multiple Innate and Adaptive Immune Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Jung YJ; Lee Y; Lee JS; Lee YN; Park S; Kang SM
    PLoS One; 2015; 10(10):e0139916. PubMed ID: 26468884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal immunization with a low-energy electron inactivated respiratory syncytial virus vaccine protects mice without Th2 immune bias.
    Eberlein V; Rosencrantz S; Finkensieper J; Besecke JK; Mansuroglu Y; Kamp JC; Lange F; Dressman J; Schopf S; Hesse C; Thoma M; Fertey J; Ulbert S; Grunwald T
    Front Immunol; 2024; 15():1382318. PubMed ID: 38646538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of STAT6 during vaccination with formalin-inactivated RSV prevents induction of Th2-cell-biased airway disease.
    Srinivasa BT; Fixman ED; Ward BJ
    Eur J Immunol; 2014 Aug; 44(8):2349-59. PubMed ID: 24796717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice.
    Boelen A; Andeweg A; Kwakkel J; Lokhorst W; Bestebroer T; Dormans J; Kimman T
    Vaccine; 2000 Nov; 19(7-8):982-91. PubMed ID: 11115725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual proinflammatory and antiviral properties of pulmonary eosinophils in respiratory syncytial virus vaccine-enhanced disease.
    Su YC; Townsend D; Herrero LJ; Zaid A; Rolph MS; Gahan ME; Nelson MA; Rudd PA; Matthaei KI; Foster PS; Dent L; Tripp RA; Lee J; Simson L; Mahalingam S
    J Virol; 2015 Feb; 89(3):1564-78. PubMed ID: 25410867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge.
    Johnson TR; Parker RA; Johnson JE; Graham BS
    J Immunol; 2003 Feb; 170(4):2037-45. PubMed ID: 12574374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
    Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
    Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.
    Lee JS; Kwon YM; Hwang HS; Lee YN; Ko EJ; Yoo SE; Kim MC; Kim KH; Cho MK; Lee YT; Lee YR; Quan FS; Kang SM
    Vaccine; 2014 Oct; 32(44):5866-74. PubMed ID: 25173478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands.
    Shafique M; Wilschut J; de Haan A
    Vaccine; 2012 Jan; 30(3):597-606. PubMed ID: 22120195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
    Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.